Date: 2016-06-26
Type of information: Nomination
Compound:
Company: Oramed Pharmaceuticals (Israel)
Therapeutic area: Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: • On July 26, 2016, Oramed Pharmaceuticals announced the appointment of Dr. Roy Eldor to the newly created position of Chief Medical Director. Dr. Roy Eldor is an endocrinologist, internist and researcher with over twenty years of clinical and scientific experience. He is currently Director of the Diabetes Unit at the Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center. Prior to that, Dr. Eldor served as Principal Scientist at Merck Research Laboratories, Clinical Research – Diabetes & Endocrinology, Rahway, New Jersey. He has previously served as a senior physician in internal medicine at the Diabetes Unit in Hadassah Hebrew University Hospital, Jerusalem, Israel; the Diabetes Division at the University of Texas Health Science Center in San Antonio, Texas (under the guidance of Dr. R.A. DeFronzo).
Financial terms:
Latest news:
